Multimodal capture − antibody-independent lateral flow immunoassay based on AuNF − PMBA for point-of-care diagnosis of bacterial urinary tract infections

Pengcheng Wu,Wanchao Zuo,Yufeng Wang,Qinfang Yuan,Jun Yang,Xinmei Liu,Hui Jiang,Jianjun Dai,Feng Xue,Yanmin Ju

DOI: https://doi.org/10.1016/j.cej.2022.139021

IF: 15.1

2023-01-01

Chemical Engineering Journal

Abstract:Bacterial urinary tract infections cause huge challenges to public health and require rapid diagnostic methods, while lateral flow immunoassay (LFIA) belongs to the most known point-of-care detection technology. Capture-antibody (CA) is used for labeling targets in traditional LFIA, yet the production of antibodies is time-consuming and expensive. In this study, we reported a multimodal CA-independent LFIA (MCI-LFIA) method for rapid diagnosis of bacterial urinary tract infections with high flexibility and accuracy. The assay employs p-mercaptophenylboronic acid-modified Au nanoflower (namely AuNF-PMBA nanomaterials) as multifunctional labels, which possess colorimetric-Raman-photothermal properties and outstanding bacteria capture ability. Take Escherichia coli (E. coli) as model bacteria, the limit of detection (LOD) of this MCI-LFIA for E. coli was 103 cfu/mL by naked-eye, which is three orders of magnitude lower than conventional CA-dependent sandwich method. For quantitative detection, LOD was 103 cfu/mL in colorimetric mode, 102 cfu/mL in Raman mode and 102 cfu/mL in photothermal mode. Significantly, the developed AuNF − PMBA-based MCI-LFIA successfully detected target pathogens in clinical E. coli-positive human urine samples within 45 min with high accuracy. This diagnostic platform may be easily adapted for detection of other target pathogens for bacterial diseases in point-of-care settings with good reproducibility and excellent specificity.

engineering, chemical, environmental